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Selection of appropriate osteoinductive growth factors, suitable delivery method and proper
supportive scaffold are critical for a successful outcome in bone tissue engineering using
bone marrow stromal cells (BMSC). This study examined the molecular and functional
effect of a combination of adenoviral mediated expression of bone morphogenetic protein-2
(BMP2) in BMSC and recently developed and characterized, biodegradable Poly(L-lactide-
co-є-caprolactone){poly(LLA-co-CL)}scaffolds in osteogenic molecular changes and
ectopic bone formation by using in vitro and in vivo approaches. Pathway-focused custom
PCR array, validation using TaqMan based quantitative RT-PCR (qRT-PCR) and ALP
staining showed significant up-regulation of several osteogenic and angiogenic molecules,
including ALPL and RUNX2 in ad-BMP2 BMSC group grown in poly(LLA-co-CL) scaffolds
both at 3 and 14 days. Micro CT and histological analyses of the subcutaneously implanted
scaffolds in NOD/SCID mice revealed significantly increased radiopaque areas, percentage
bone volume and formation of vital bone in ad-BMP2 scaffolds as compared to the control
groups both at 2 and 8 weeks. The increased bone formation in the ad-BMP2 group in vivo
was paralleled at the molecular level with concomitant over-expression of a number of oste-
ogenic and angiogenic genes including ALPL, RUNX2, SPP1, ANGPT1. The increased
bone formation in ad-BMP2 explants was not found to be associated with enhanced endo-
chondral activity as evidenced by qRT-PCR (SOX9 and FGF2) and Safranin O staining.
Taken together, combination of adenoviral mediated BMP-2 expression in BMSC grown in
the newly developed poly(LLA-co-CL) scaffolds induced expression of osteogenic markers
and enhanced bone formation in vivo.
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Introduction
Bone regeneration using tissue engineering approach, which utilizes mesenchymal stem cells
grown in an osteoconductive scaffold and with osteoinductive growth factors is a promising
approach and has been studied for over a decade [1]. Bone Morphogenetic protein-2 (BMP2),
a member of a TGF-β superfamily is a potent osteoinductive growth factor. BMP2 promotes
cellular migration, proliferation and osteogenic differentiation of mesenchymal stem cells dur-
ing bone repair by regulating the expression of Runt-related transcription factor 2 (Runx2) and
Osterix (Osx) [2]. The FDA approved recombinant BMP2 (rhBMP2) protein has been utilized
in numerous preclinical and clinical studies for osteogenesis [3, 4]. Delivery of BMP2 to the
defect site is crucial for its biological activity. Owing to its short half-life and rapid diffusibility
from the applied site, supraphysiological dose is required to achieve biologic effects, making it
an expensive treatment strategy [5]. In addition, use of supraphysiological dose is associated
with side effects such as: heterotropic ossification [6], osteolysis [7] and structurally abnormal
bone formation [8]. This highlights the need for a more physiological and efficient alternative
approach for growth factor delivery. Recently, gene delivery technique, where a therapeutic
gene is delivered into a defect site by transgenes employing viral or non-viral vectors, has
gained a considerable interest in bone tissue engineering (BTE) [9–11].
Another important component in BTE is the supportive scaffold in which the bone marrow
stromal cells (BMSC) attach, proliferate, differentiate and release signaling molecules and
growth factors. An ideal scaffold is required to be biocompatible, biodegradable, must be able
to promote cellular interactions and bone formation, and have adequate mechanical and physi-
cal properties [12, 13]. In this regard, scaffolds of various materials [including metals, ceramics,
polymers (natural or synthetic) or their combination] have been tested for their applicability in
BTE. Ceramic-based scaffolds, such as tricalcium phosphate and hydroxyapatite, resemble the
inorganic bone matrix and have a good osteoconductive property. However, wider clinical
application of these materials have been hindered by their slow degradation rate and brittleness
[14], and limited ability to stimulate cell differentiation [15]. The recently developed poly
(LLA-co-CL) scaffolds have been suggested to possess excellent biodegradability and biocom-
patibility qualities required for BTE [16, 17]. These scaffolds have been extensively character-
ized for the biological and molecular response of osteoblasts [18], endothelial cells [19] as well
as human-BMSC and rat-BMSC [20, 21]. These copolymer scaffolds can be tailored to achieve
predictable degradation rate as per the various clinical need and application [12]. Owing to this
ability, copolymer scaffold can also be an ideal candidate to be used as a delivery device for var-
ious growth factors including rhBMP2. Mechanical and surface characteristics of these scaf-
folds have been successfully modified to enhance bone regeneration [22]. Both non-covalent
(physiosorption, physical entrapment) and covalent binding techniques have been used for the
delivery of rhBMP2 utilizing these copolymer scaffolds to accelerate bone regeneration in criti-
cal sized bone defects [23, 24]. Nevertheless, osteogenic ability of BMSC engineered to express
BMP2 by adenoviral system grown in poly(LLA-co-CL) scaffolds has not been tested and char-
acterized for use in BTE. In the current study, using BMSC grown in poly(LLA-co-CL) scaf-
folds, we showed that adenoviral mediated expression of BMP2 in BMSC is associated with
significantly enhanced osteogenic ability both in vitro and in vivo.
Materials and Methods
Cell Culture
Well characterized primary human BMSC were purchased from StemCell Technologies (Cat.
number: MSC-001F, Vancouver, British Columbia, Canada) and expanded using MesenCult
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Proliferation Kit (StemCell Technologies, Part ID 05411) following standard culture protocol.
All cell culture experiments were carried out at a humidified atmosphere of 37°C and 5% CO2.
For validation of the osteogenic and angiogenic gene expression changes induced by adenoviral
mediated BMP2 expression in BMSC, commercially available human BMSC from two addi-
tional donors were purchased and used (henceforth referred to as donor 2 and 3 BMSC) as
described in S1 Text.
Preparation of BMSC seeded scaffolds
Poly(LLA-co-CL) scaffolds were fabricated, using the solvent-casting particulate-leaching
method as described previously [16, 21]. For in vitro experiments, scaffolds (diameter12mm,
height1.3mm, porosity: 85% and pore size: 350μm on average) were placed on the bottom of
48-well plates, pre-wetted with the culture media and incubated overnight at a humidified
atmosphere of 37°C and 5% CO2. BMSC were seeded at a density of 5 × 10
4 cells/scaffold.
Adenoviral expression vector construction and transduction of BMSC
Replication-deficient adenoviral expression vector carrying the coding sequences of BMP2
gene (reference sequence: NM_001200.2)(ad-BMP2)and eGFP gene coding for enhanced green
fluorescent protein (eGFP) was purchased from Cyagen Biosciences Inc. Adenoviral vector car-
rying only eGFPcoding sequences (ad-GFP) was used as a control. Adenoviral particles were
generated by transfecting HEK 293 cells (ATCC-CRL-1573) with Pac I digested constructs.
Early passage (passage 2–3) BMSC were infected as monolayer culture with respective adenovi-
ruses (multiplicity of infection, MOI = 100 to 150) to obtain 80–90% infection efficiency as
examined under the fluorescent microscope. BMSC infected with ad-BMP2 and ad-GFP will
henceforth be referred to as ‘ad-BMP2 BMSC’ and ‘ad-GFP BMSC’ respectively. To verify up-
regulation of BMP2mRNA in ad-BMP2 BMSC in monolayer, cells were harvested after 48
hours of adenoviral infection. To determine the amount of secreted BMP2 after 48 hours of
adenoviral infection, culture supernatant was collected and analyzed using commercially avail-
able ELISA kit following manufacturer’s instructions. Further, BMSC were seeded at a density
of 5 × 104 cells/scaffold after 48 hours of infection in monolayer with the respective adenoviral
particles in Poly(LLA-co-CL) scaffolds. BMSC grown in scaffolds were harvested after 3 and 14
days for mRNA expression analysis. Culture supernatants were also collected on the respective
time points for ELISA assay.
Total RNA extraction
Total RNA from the in vitro seeded scaffolds were extracted using Maxwell1 16 LEV sim-
plyRNA Kit (Cat no: AS1270, Promega) on a Maxwell1 16 instrument following the manufac-
turer’s protocol. Quantity and purity of the total RNA was determined using a Nanodrop
Spectrophotometer (ThermoScientific Nano Drop Technologies, Wilmington, DE, USA). Agi-
lent 2100 Bio analyzer (Agilent Technologies) was used to examine the integrity of RNA (data
not shown).
Expression analysis of osteogenesis and angiogenesis related genes in
vitro
To examine the range of genes modulated by BMP2 over-expression in BMSC in the 3D-scaf-
fold (in vitro), a custom PCR array (Cat no: 330131, SuperArray Bioscience, Frederick, MD,
USA) containing primer pairs for 30 genes related to osteogenesis and angiogenesis (Table 1)
was used. Total RNA from 3 biological replicates (n = 3) of both ad-GFP and ad-BMP2 groups
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were used for cDNA synthesis at 3 and 14 days. PCR amplification was performed using the
following cycling conditions: 95°C for 10 min, (95°C for 15 sec, and 60°C for 1 min) x 40 cycles
in ABI Prism Sequence Detector 7900 HT (Applied Biosystems, Foster City, USA). Pre- and
post- PCR quality control measures, as recommended by the manufacturer, were strictly fol-
lowed. PCR array data were analysed as described previously [25]. Briefly, threshold cycle (Ct)
was used to calculate 2-ΔCt value for each gene using PCR Array Data Analysis Web Portal
(SABiosciences). 2-ΔCt values were then exported to microarray data analysis software
(J-Express 2012). For statistical analysis, unsupervised hierarchical clustering and significance
analysis of microarray (SAM) tests were used. Differentially expressed genes with false discov-
ery rate (FDR) = 0 were considered to be significantly modulated genes.
Table 1. Genes used in the custom qRT-PCR array.
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Reverse transcription and quantitative RT-PCR (qRT-PCR) using
TaqMan assays
Three hundred Nano grams of total RNA was converted to cDNA by reverse transcription
reaction using a high capacity cDNA Archive Kit (Applied Biosystems, Carlsbad, CA, USA).
BMP2 TaqMan assay (Hs00154192_m) was used to verify the expression of BMP2mRNA in
adenovirus transduced BMSC. The in vitro PCR array results were independently validated by
performing qRT-PCR using TaqMan assays for selected key genes {ALPL (Hs01029144_m1),
RUNX2(Hs00231692_m1), BGLAP (Hs01587814_g1) and VEGFA (Hs00900055_m1)}.
GAPDH (Hs99999905_m1) was used as an endogenous control. All qRT-PCR amplifications
were performed on ABI Prism Sequence Detector 7900 HT (Applied Biosystems, Foster City,
USA) with standard cycling conditions. Comparative 2-ΔΔ Ct method was used to quantify the
relative mRNA expression.
Alkaline phosphatase (ALP) staining
ALP staining was done to analyze the osteoblastic differentiation potential of BMSC transduced
with ad-BMP2. After 48 hours of infection, cells were trypsinized and 2 × 104 cells were seeded in
monolayer on 4-well culture dish. ALP staining was done on day 3, and 14. Briefly, cells were
washed with phosphatase buffer saline and stained for alkaline phosphatase (ALP) activity using
Napthol AS-TR phosphate and fast red violet B salt (Sigma-Aldrich) as described previously [26].
In vivo subcutaneous implant model in nonobese severe combined
immunodeficient (NOD/SCID) mice
a. Preparation of BMSC seeded scaffolds. Poly(LLA-co-CL) scaffolds (diameter 6mm,
height1.3mm and pore size of 90–500μm) were prepared as described previously [16, 21].
The scaffolds were placed on the bottom of 96-well plates, pre-wetted with the culture medium
and incubated overnight at a humidified atmosphere of 37°C and 5% CO2. 5 × 10
5 BMSC were
seeded in each scaffold after 48 hours of infection with the respective adenoviral particles, incu-
bated overnight at a humidified atmosphere of 37°C and 5% CO2 and implanted subcutane-
ously in NOD/SCID mice. Scaffolds with untransduced BMSC or without any BMSC (only
scaffold) were used as additional controls in the in vivo experiments.
b. Surgical Implantation of scaffolds. All animal experiments were approved by the Nor-
wegian Animal Research Authority and conducted according to the European Convention for
the Protection of Vertebrates used for Scientific Purposes, with local approval number 4940. Six-
teen NOD-SCID mice (6–8 weeks old, Taconic Farms, Denmark) (8 mice each for both 2 and 8
week time-points) were used for subcutaneous implantation of scaffolds. The animals were
anesthetized by subcutaneous injection Midazolam 5mg/ml/Hyponorm solution. Two midline
surgical incisions of approximately 2cm in length were made on the back of mice, which were
extended laterally by blunt dissection and a subcutaneous pouch was created. Each animal
received four randomly allocated scaffold implants of the following groups: i) ad-GFP (9 repli-
cates), ii) ad-BMP2 (9 replicates), iii) untransduced (9 replicates) and iv) scaffold only group (5
replicates). The scaffolds were implanted in such a way that scaffolds from all the experimental
groups are implanted in all possible locations among following four sites: upper right side,
upper left side, lower left side and lower right side. Wounds were closed with Histoacryl Tissue
Adhesive (n-butyl cyanoacrylate) (3M, St. Paul, MN, USA). Animals were euthanized with CO2
inhalation and subsequent cervical dislocation at 2 and 8 weeks. Three of the randomly selected
scaffolds from only scaffold group and six scaffolds each from un-transduced, ad-GFP and ad-
BMP2 groups at 2 week time point were divided into two equal halves. One half of the scaffolds
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was stored in RNA later (Ambion) for total RNA extraction and the other half was formalin
fixed (4% buffered formalin), decalcified (12.5% EDTA and 2.5% PFA in phosphate buffered
saline) and paraffin embedded for histological analysis. Remaining scaffolds from all of the
experimental groups were also formalin fixed and used for histological analysis. At 8 weeks, 3
randomly selected scaffolds from all of the groups were used for micro CT analysis. All remain-
ing scaffolds were formalin fixed-paraffin embedded for histological analysis.
Expression analysis of osteogenesis and angiogenesis related genes for
in vivo scaffold explants
For in vivo scaffold explants (2 weeks), six hundred Nano grams of total RNA from 6 biological
replicates (n = 6) of both ad-GFP and ad-BMP2 BMSC groups were converted to first strand
cDNA using RT2 First Strand Kit (C-03, SABiosciences, Frederick, MD, USA). To examine the
range of genes modulated by BMP2 over-expression, a custom PCR array (Cat no: 330131,
SuperArray Bioscience, Frederick, MD, USA) containing primer pairs for 30 genes related to
osteogenesis and angiogenesis (Table 1) was used. PCR amplification and statistical analysis
was performed as described beforehand for the in vitro scaffolds.
Histological analysis
The paraffin embedded specimens were cut into 5 μm sections. The sections were deparaffinized,
rehydrated in xylene and graded ethanol stained with Hematoxylin and Eosin. Safranin O staining
was performed to visualize newly synthesized cartilaginous extracellular matrix glycosaminogly-
can. Briefly, sections were stained with 0.1% Safranin O and 0.05% fast green was used as counter
stain. The stained sections were dehydrated, cleared and mounted using resinous medium.
Micro computed tomography analysis (μCT)
The in vivo scaffold explants harvested at 8 weeks were scanned with a SkyScan 1172 X-
ray μCT imaging system (Aartselaar, Belgium) at 10 μm resolution with a voltage of 60 kV with
0.5 aluminum filters. The Projection image was reconstructed using Nrecon software. The
quantitative analysis of the image was performed by CTan software provided by SkyScan. A
global threshold of 70–255 was applied to all the samples and the region of interest (ROI) was
selected by outlining the scaffolds. The percent of binarized volume within ROI represented
the percent of bone volume in the scaffolds.
Statistical analyses
Data are expressed as mean ± standard error of the mean (SEM). Statistical analysis for the
comparison of means between two groups was performed with Student’s t-test; whereas
ANOVA test with Bonferroni post hoc analysis was used for comparison between multiple
groups. Statistical analyses were performed using GraphPad Prism software version 5.00 for
Windows (GraphPad Software, San Diego California USA, www.graphpad.com), with the level
of significance set at 5%.
Results
BMP2 adenoviral expression vector up-regulated endogenous BMP2
mRNA and secreted protein levels
BMSC transduced with ad-GFP and ad-BMP2 viral particles demonstrated similar morphology
in monoculture (Fig 1A–1D). ad-BMP2 BMSC grown in monolayer expressed significantly
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higher levels of BMP2mRNA and secreted BMP2 protein at day 3 as compared to the control
ad-GFP BMSC (Fig 1E and 1F). In parallel, significantly higher levels of BMP2mRNA and
secreted BMP2 protein was found in ad-BMP2 BMSC grown in 3D scaffold as compared to the
control ad-GFP transduced cells both at day 3 and 14 (Fig 1G–1I).
BMP2 over-expression is associated with up-regulation of osteogenic
and angiogenic markers in vitro
Custom PCR array was used to examine differentially expressed osteogenesis and angiogenesis
related genes with BMP2 over-expression. SAM analysis showed significant (FDR = 0) up-
Fig 1. BMP2 adenoviral expression vector increased up-regulation of BMP2 in BMSC.Representative images of BMSC in monolayer transduced with
ad-GFP (A, brightfield and B, fluorescent) and ad-BMP2 (C, brightfield and D, fluorescent) adenoviral particles. Significant up-regulation of BMP2mRNA (E)
and secreted BMP2 protein in the conditioned medium (F) at day 3 in ad-BMP2 BMSC in monolayer as compared to the ad-GFP BMSC. Error bars in (E)
represent SEM of 3 repeated experiments (n = 3) done in 3 technical replicates. Student’s-t test was performed for statistical analysis. Error bars in (F)
represent SEM of 3 repeated experiments. Student’s t-test was performed for statistical analysis. (G) 5× 104 BMSC were seeded in each poly(LLA-co-CL)
scaffolds and harvested after 3- and 14-days for qRT-PCR. qRT-PCR demonstrated significant up-regulation of endogenous BMP2mRNA in ad-BMP2
BMSC as compared to the ad-GFP BMSC both at 3- and 14- days. BMP2mRNA level was normalized toGAPDHmRNA level. Error bars represent SEM of 3
repeated experiments (n = 3) done in 3 technical replicates. Student’s t-test was performed for statistical analysis. (H-I) Higher levels of secreted BMP2 were
observed by using ELISA assay in the culture supernatant of ad-BMP2 BMSC as compared to the ad-GFP transduced cells both at 3- and 14- days. Error
bars in (H and I) represent SEM of 3 repeated experiments. Student’s t-test was performed for statistical analysis.
doi:10.1371/journal.pone.0147507.g001
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regulation of the early osteogenic marker ALPL at day 3 in ad-BMP2 BMSC grown in 3D-scaf-
fols as compared to the control ad-GFP BMSC (Fig 2A). At day 14, ALPL, RUNX2, BMP6,
BGLAP (osteocalcin) and BMP7, the osteogenesis related genes, were found to be over-
expressed in ad-BMP2 BMSC (Fig 2B). Additionally, mRNA expression levels of angiogenic
molecules, such as FLT1 (VEGFR1) and its ligands VEGFA and PGF, were significantly upre-
gulated in ad-BMP2 BMSC respectively at 3 days and 14 days (Fig 2A and 2B). Independent
validation of the differentially expressed selected genes, as identified by PCR array, was done
by performing qRT-PCR using TaqMan assays for ALPL, RUNX2 and BGLAP and VEGFA.
Consistent with the PCR array results, ALPL was found to be significantly up-regulated in ad-
BMP2 BMSC and untransduced BMSC both at day 3 (P<0.001) and day 14 (P<0.001) (Fig 2C
and 2D). Similarly, mRNA levels of RUNX2 (P<0.001), BGLAP (P<0.001) and VEGFA
(P<0.001) were significantly higher in ad-BMP2 as compared to that of ad-GFP BMSC and
untransduced BMSC at day 14 (Fig 2D). To confirm the induction of ALPLmRNA at the pro-
tein level, ALP staining was performed. ALP level was found to be significantly induced at day
3 and the elevated level was also maintained at day 14 in ad-BMP2 BMSC as compared to the
barely detectable levels in ad-GFP BMSC and untransduced BMSC (Fig 2E). Further, over-
expression of mRNA levels of ALPL, RUNX2 and VEGFA with adenoviral mediated BMP2
over-expression was confirmed in two additional donors as described in S1 Text and S1 Fig.
BMP2 over-expression induced bone formation in 3D-scaffold explants
in NOD/SCID mice
Ability of BMP2 to induce ectopic bone formation in 3D-scaffold was examined by subcutane-
ously implanting 3D-scaffold seeded with ad-BMP2, ad-GFP, untransduced BMSC and only
scaffold controls (Fig 3A). With tactile and visual inspection, ad-BMP2 scaffold explants were
found to be harder in consistency with richer vascular networks as compared to that of the con-
trol-explants both at 2 and 8 weeks (data for 2 weeks are not shown) (Fig 3B). Micro CT analy-
sis revealed no radiopaque bone like structures in the scaffold explants from only scaffold
(n = 3), untransduced (n = 3) and ad-GFP (n = 3) groups at 8 weeks (Fig 3C–3E). In contrast,
all analyzed replicates (n = 3) from ad-BMP2 explants at 8 weeks revealed formation of dense
bone like structure in the periphery as well as inside of the scaffold explant (Fig 3F). Quantifica-
tion of ectopic bone formation in the scaffolds showed significantly higher % volume of radi-
opaque mass in ad-BMP2 explants as compared to the controls (Fig 3G). Histological
examination of H & E stained sections was next performed to confirm the formation of bone
structures in ad-BMP2 explants. Similar to the microCT findings, no bony structures were
detected in all replicates of only scaffold, untransduced and ad-GFP explants both at 2 and 8
weeks (Fig 3H–3M). However, formation of bony structures (black arrows) was detected at the
periphery of the scaffold explants in all replicates (9/9) of ad-BMP2 BMSC at 2 weeks (Fig 3N).
At 8 weeks, formation of bony structures (green arrows) was more extensive with bony trabec-
ulae extending throughout the whole thickness of the scaffold explants in all of replicates (6/6)
examined (Fig 3O). Bony structure consisted of numerous osteocyte like cells both at 2 (black
arrowheads, inset N) and 8 (green arrowheads, inset O) weeks. No inflammatory cells, except
occasional multinucleated giant cells, were seen in all groups (Fig 3H–3O).
BMP2 over-expression mediated bone formation is associated with up-
regulation of osteogenic markers in the in vivo 3D-scaffold explants
Custom PCR array was used to examine differentially expressed osteogenesis and angiogenesis
related genes in 3D-scaffold explants at 2 weeks. Unsupervised clustering using the significantly
modulated genes revealed two distinct clusters for ad-GFP and ad-BMP2 explants (Fig 4). SAM
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Fig 2. BMP2 over-expression led to up-regulation of osteogenic and angiogenic molecules in vitro. 5 × 104 ad-BMP2 or ad-GFP BMSC were seeded
in each Poly(LLA-co-CL) scaffolds and harvested after 3 and 14 days for custom PCR array and TaqMan based qRT-PCR. (A) With SAM analysis, ALPL and
FLT1mRNA levels were found to be significantly (FDR = 0) up-regulated at 3-days in ad-BMP2 BMSC. (B) More osteogenic and angiogenic markers were
significantly induced at 14-days in ad-BMP2 BMSC as compared to the ad-GFP BMSC group. (C and D) Array results for ALPL, RUNX2, BGLAP and VEGFA
genes were independently validated in ad-BMP2 BMSC by using TaqMan qRT- PCR. Error bars represent SEM of 3 repeated experiments (n = 3) done in 3
technical replicates. ANOVA test with Bonferroni post hoc analysis was performed for statistical analysis in C and D. ***, p<0.001; *, P<0.01; ns, non-
significant. (E) Representative images demonstrating higher alkaline phosphatase activity in ad-BMP2 BMSC in monolayer as compared to the ad-GFP
BMSC and untransduced BMSC. Experiments were repeated at least three times.
doi:10.1371/journal.pone.0147507.g002
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Fig 3. Over-expression of BMP2 induced ectopic bone formation in poly(LLA-co-CL) scaffold explants in subcutaneous NOD/SCID mice model.
Ability of BMP2 to induce ectopic bone formation in poly(LLA-co-CL) scaffold was examined by subcutaneously implanting scaffold seeded with 5 ×10 5 ad-
BMP2 BMSC or control BMSC in NOD/SCID mice. (A) Schematic illustration indicating location of the scaffold implantation sites in the back of each mouse.
(B) Representative images of the scaffold explants at 8 weeks revealed more vascularity in ad-BMP2 BMSC as compared to the control explants. (C-F) To
evaluate the ectopic bone formation, scaffold explants at 8 weeks were examined by micro CT. No radiopaque bone like object was detected in the control
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analysis showed significant (FDR = 0) up-regulation of osteogenesis related genes such as SPP1
(16.3 fold change), ALPL (9.9 fold change), BMP6 (3.3 fold change) RUNX2 (2.3 fold change),
in ad-BMP2 explants as compared to the ad-GFP explants (Fig 4). Additionally, ANGPT1 (1.8
fold change), an angiogenic factor that modulates endothelial differentiation, was found to be
significantly increased in ad-BMP2 explants (Fig 4). Of note, mRNA levels of SOX9, a key tran-
scriptional factor required for the successive steps of chondrogenesis [27] was significantly
down-regulated (2.6 folds) in ad-BMP2 explants (Fig 4). In parallel, mRNA levels of FGF2, an
upstream positive regulator of SOX9 [28], was also under-expressed (2.3 folds) in ad-BMP2
explants (Fig 4).
BMP2 over-expression mediated bone formation is not associated with
enhanced chondrogenic activity
Significant down-regulation of SOX9 and FGF2mRNA levels in ad-BMP2 explants led us to
investigate the presence of cartilaginous extracellular matrix glycosaminoglycan by Safranin in
the bony structures. No positive staining for Safranin O was detected in the bony structures in
ad-BMP2 scaffold explants both at 2 and 8 weeks (Fig 5A and 5B). However, strong positivity
was observed in the positive control (cranial base of mouse embryo E14) (Fig 5C).
Discussion
Employing recently developed biodegradable poly(LLA-co-CL) scaffolds as a carrier, the cur-
rent study examined the role of BMSC engineered to express BMP2 by adenovirus vector in
bone formation. Our results demonstrated that adenoviral mediated BMP2 delivery signifi-
cantly induced osteogenic differentiation of BMSC grown in poly(LLA-co-CL) scaffolds in
vitro as well as bone formation ability in vivo.
Although the therapeutic importance of BMP2 in bone regeneration is well recognized, the
precise and physiological delivery of BMP2 at the defect site is difficult to achieve [5]. It has
been demonstrated that a short-term expression of the BMP2 is sufficient to irreversibly induce
bone formation by BMSC [29], suggesting that a transient expression of BMP2 might be suffi-
cient for cell-mediated BMP2 therapy for bone regeneration. These findings support the use of
adenoviral mediated gene delivery system which has been shown to induce a transient (less
than 2 weeks) gene expression in vivo [30]. In the current study, ad-BMP2 BMSC expressed
significantly higher levels of BMP2mRNA and secreted protein (Fig 1), indicating that adeno-
viral mediated BMP2 transduction in BMSC was functional. PCR array showed significant up-
regulation of several key osteogenic marker genes (ALPL, RUNX2, BGLAP, BMP6, BMP7) in
ad-BMP2 at day 3 or day 14 in vitro. These results indicate that BMP2 was able to differentiate
BMSC seeded in scaffolds (in vitro) towards an osteogenic pathway. Up-regulation of osteo-
genic marker genes was also observed in ad-BMP2 BMSC from donor 2 and 3 (S1 Fig), suggest-
ing that osteogenic effects of BMP2 was not restricted to a limited type of BMSC strains. In
addition to osteoinduction, angiogenesis is considered essential for bone regeneration [31].
groups (C), (D) and (E). However, radiopaque bone like areas were found at the periphery as well as inside of the scaffold in ad-BMP2 explants (F). Red line
across the scaffold indicates imaginary plane for transverse section. (G) Quantification of radiopaque bone like objects in the scaffold explants at 8-weeks
demonstrated significant amount of bone formation in ad-BMP2 scaffolds. ANOVA test with Bonferroni post hoc analysis was performed for statistical
analysis in (G). Error bars represent SEM. ***, P<0.001. (H-O) Representative images of H & E stained formalin fixed paraffin embedded sections of scaffold
explants from different experimental groups at 2- and 8-weeks. (H-M) Formation of bony structures was not detected in only scaffold, untransduced or ad-
GFP groups both at 2- and 8-weeks. (N) As early as 2-weeks, formation of bony structures (black arrows) mostly at the periphery of the scaffold explants was
observed in ad-BMP2 BMSC group. (O) Extensive bone formation (green arrows) with bony trabeculae extending throughout the thickness of the Scaffolds
was found in 8-weeks in ad-BMP2 BMSC. Bony structure consisted of numerous osteocyte like cells both at 2- (black arrowheads, inset N) and 8- weeks
(green arrowheads, inset O).
doi:10.1371/journal.pone.0147507.g003
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Fig 4. BMP2 over-expressionmediated bone formation is associated with up-regulation of osteogenic
markers in the in vivo scaffold explants.Custom PCR array was used to examine differentially expressed
osteogenesis and angiogenesis related genes in scaffold explants at 2 weeks. Unsupervised hierarchal
clustering demonstrated two separate clusters of the biological replicates (n = 6) from ad-BMP2 and ad-GFP
BMSC groups. SAM analysis revealed significant up-regulation (FDR = 0) of a number of osteogenesis
related genes such as SPP1 (osteopontin), ALPL, RUNX2, BMP6, ANGPT1 in ad-BMP2 explants as
compared to the ad-GFP explants.
doi:10.1371/journal.pone.0147507.g004
Fig 5. BMP2 over-expressionmediated bone formation is not associated with enhanced chondrogenic activity. Formalin fixed paraffin embedded
sections of ad-BMP2 explants at 2- and 8- weeks were stained with safranin O and counterstained with fast green. Bony structures in the scaffold explants (A
and B) were negative for safranin O staining whereas the positive control (C, cranial base of mouse embryo E14) was intensely positive.
doi:10.1371/journal.pone.0147507.g005
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Angiogenesis is a complex process requiring a coordinated interplay between growth factors,
their receptor systems and down-stream signaling pathways [32]. In the present study, mRNA
expression levels of FLT1 (VEGFR1) and its ligands VEGFA and PGF, were significantly upre-
gulated in ad-BMP2 BMSC respectively at day 3 and day 14 (Fig 2), suggesting that BMP2
expression was able to induce pre-angiogenic transcriptional program in BMSC. In line to
these findings, previous studies have demonstrated up-regulation of VEGFA and PGF in pre-
osteoblast like mouse cells [33] and human osteoblasts [34] with rhBMP2 treatment. Taken
together, adenoviral mediated BMP2 expression in BMSC grown in poly(LLA-co-CL) scaffolds
in vitro was able to induce osteogenic differentiation and to program BMSC towards more
angiogenic genotype.
Examination of osteogenic ability of adenoviral mediated BMP2 expression was subse-
quently performed by subcutaneous implantation of poly(LLA-co-CL) scaffold seeded with
BMSC in NOD/SCID mice. On gross visual examination, scaffold explants from ad-BMP2
group both at 2- and 8-weeks were reddish in color as compared to the explants from control
groups (Fig 3B), indicating that these scaffold explants were richer in vascular supply. Support-
ing these observations, mRNA levels of ANGPT1 (angiopoietin-1), which is crucial to the mat-
uration of newly formed blood vessels, was significantly up-regulated in ad-BMP2 scaffold
explants as compared to the ad-GFP control explants (Fig 4). This is in line with the in vitro
results where BMP2 expression led to significant up-regulation of other pro-angiogenic mole-
cules in ad-BMP2 BMSC (Fig 2 and S1 Fig). MicroCT analysis revealed no radiopaque bone
like mass in any of the control groups, whereas a significant amount of radiopaque mass could
be detected in the ad-BMP2 explants (Fig 3C–3G). Mirroring these results, histological exami-
nation of H&E stained sections showed no bony structures in the scaffold explants from any of
the control groups, both at 2-and 8-weeks (Fig 3H–3M). In contrast, formation of bony struc-
tures could be identified in ad-BMP2 scaffold explant as early as 2-weeks, with more extensive
bone formation by 8-weeks (Fig 3N and 3O). Numerous osteocytes like cells present in the
bony structures in ad-BMP2 explants (Fig 3N and 3O, insets) suggested that the newly formed
bone in the scaffolds was indeed a vital bone. Overall, these findings indicate that the adenovi-
ral mediated expression of BMP2 in BMSC could induce formation of vital bony structures in
poly(LLA-co-CL) scaffolds. Unsupervised hierarchical cluster analysis of the PCR array data
showed a distinct mRNA profile of the genes related to osteogenesis and angiogenesis in ad-
BMP2 explants as compared to ad-GFP explants (Fig 4), indicating a role for BMP2 in the reg-
ulation of these genes. SAM analysis further identified a number of osteogenic genes like
RUNX2, ALPL, SPP1 and BMP6 to be significantly up-regulated in the ad-BMP2 explants. Col-
lectively, these findings indicate that BMP2 enhances bone formation in poly(LLA-co-CL) scaf-
fold seeded with ad-BMP2 BMSC by regulating the expression of key osteogenic genes such as
RUNX2, ALPL, SPP1 and BMP6.
Although some studies [35, 36] have suggested endochondral ossification as the mode for
ectopic bone formation in the scaffold explants, the precise mechanism is currently unknown.
In the current study, mRNA levels of SOX9 and its upstream regulator, FGF2, was significantly
under-expressed in ad-BMP2 explants at 2 weeks (Fig 4), suggesting that BMP2 mediated bone
formation in poly(LLA-co-CL) scaffold explants was not related to enhanced chondrogenic
activity. Supporting this suggestion, no positivity for safranin O staining was detected in bony
structures in 2- and 8-weeks ad-BMP2 scaffold explants, whereas the positive control (cranial
base of mouse embryo E14) was intensely positive (Fig 5). Hence, further studies are necessary
to uncover the underlying mechanism of ectopic bone formation in scaffold explants.
In conclusion, results from the current study demonstrated that adenoviral mediated BMP2
delivery significantly induced mRNA expression levels of osteogenic and pro-angiogenic mole-
cules in vitro in BMSC grown in recently developed, biodegradable poly(LLA-co-CL) scaffolds.
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Additionally, BMP2 over-expressing BMSC significantly enhanced bone formation in poly
(LLA-co-CL) scaffolds in subcutaneous mouse model, with concomitant up-regulation of key
osteogenic markers. Given the superior biodegradability, biocompatibility and mechanical
properties of poly(LLA-co-CL) scaffolds and growing popularity of adenoviral vectors for gene
therapy [37], their combination together with BMSC might, in future, be useful for bone regen-
eration therapy.
Supporting Information
S1 Fig. BMP2 induced in up-regulation of ALPL, RUNX2 and VEGFAmRNA expression
levels in ad-BMP2 BMSC from donor 2 and 3.mRNA levels of BMP2 (A), ALPL (B and D),
RUNX2 (C and E), or VEGFA (F), were significantly over-expressed at day 3 or 14 in ad-BMP2
BMSCs from donors 2 grown in 3D scaffolds as compared to the control ad-GFP BMSC.
mRNA levels of BMP2 (G), ALPL (H and J), RUNX2 (I and K), were significantly over-
expressed at day 3 or 14 in ad-BMP2 BMSCs in ad-GFP BMSC from donors 3. Error bars rep-
resent SEM of 3 repeated experiments (n = 3) done in 3 technical replicates. ANOVA test with
Bonferroni post hoc analysis was performed for statistical analysis.  P<0.001; P = 0.001–
0.01.
(TIF)
S1 Text. Supplementary Methods and Results.
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